Citations

Showing 10 of 108104 citations.

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
Harrison, Claire , Garcia, Jacqueline S. , Somervaille, Tim C. P. , Foran, James M. , Verstovšek, Srđan , Jamieson, Catriona , Mesa, Ruben A. , Ritchie, Ellen K., Tantravahi, Srinivas K., Vachhani, Pankit , O'Connell, Casey L., Harb, Jason, Hutti, Jessica E., Holes, Leanne, Masud, Abdullah A., Nuthalapati, Silpa, Potluri, Jalaja, Pemmaraju, Naveen , Harrison, Claire N , Mesa, Ruben , Komrokji, Rami S , Pemmaraju, Naveen , Verstovsek, Srdan , Garcia, Jacqueline S , Somervaille, Tim C.P. , Foran, James M , Jamieson, Catriona , Ritchie, Ellen K., Tantravahi, Srinivas K., Vachhani, Pankit , O'Connell, Casey L., Harb, Jason, Hutti, Jessica E., Holes, Leanne, Masud, Abdullah A., Nuthalapati, Silpa, Potluri, Jalaja

Mayo Clinic

Journal of Clinical Oncology | February 18, 2022 | Volume: 40 | Issue: 15 | Pages: 1671-1680

10.1200/jco.21.02188 | PMID 35180010 Get It

PURPOSE Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy and safety of adding BCL-XL/BCL-2 inhibitor navitoclax to ruxolitinib therapy in patients with myelofibrosis with progression or suboptimal response to ruxolitinib monotherapy (ClinicalTrials.gov identifier: NCT03222609 ). METHODS Thirty-four adult patients with intermediate-/high-risk myelofibrosis who had progression or suboptimal response on stable ruxolitinib dose (≥ 10 mg twice daily) were administered navitoclax at 50 mg once daily starting dose, followed by escalation to a maximum of 300 mg once daily in once in weekly increments (if platelets were ≥ 75 × 109/L). The primary end point was ≥ 35% spleen volume reduction (SVR35) from baseline at week 24. Secondary end points included ≥ 50% reduction in total symptom score (TSS50) from baseline at week 24, hemoglobin improvement, change in bone marrow fibrosis (BMF) grade, and safety. RESULTS High molecular risk mutations were identified in 58% of patients, and 52% harbored ≥ 3 mutations. SVR35 was achieved by 26.5% of patients at week 24, and by 41%, at any time on study, with an estimated median duration of SVR35 of 13.8 months. TSS50 was achieved by 30% (6 of 20) of patients at week 24, and BMF improved by 1-2 grades in 33% (11 of 33) of evaluable patients. Anemia response was achieved by 64% (7 of 11), including one patient with baseline transfusion dependence. Median overall survival was not reached with a median follow-up of 21.6 months. The most common adverse event was reversible thrombocytopenia without clinically significant bleeding (88%). CONCLUSION The addition of navitoclax to ruxolitinib in patients with persistent or progressive myelofibrosis resulted in durable SVR35, improved TSS, hemoglobin response, and BMF. Further investigation is underway to qualify the potential for disease modification.
Experimental Study of Aperiodic Plane Wave Imaging for Ultrafast 3-D Ultrasound Imaging
Bae, Sua , Kim, Bae-Hyung , Fatemi, Mostafa , Fatemi, Mostafa , Bae, Sua , Kim, Bae-Hyung , Alizad, Azra , Song, Tai‐Kyong

Mayo Clinic

IEEE Transactions on Biomedical Engineering | February 18, 2022 | Volume: 69 | Issue: 8 | Pages: 2679-2690

10.1109/tbme.2022.3152212 | PMID 35180073 Get It

Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis
Sonbol, Mohamad Bassam , Mazza, Gina L. , Mi, Lanyu , Oliver, Thomas , Starr, Jason S. , Gudmundsdottir, Hallbera , Hobday, Timothy J. , Hobday, Timothy, Sonbol, Mohamad B , Mazza, Gina L , Gudmundsdottir, Hallbera , Oliver, Thomas, Cleary, Sean P. , Hálfdánarson, Þorvarður R.

Mayo Clinic

The Oncologist | February 18, 2022 | Volume: 27 | Issue: 7 | Pages: 573-578

10.1093/oncolo/oyac049 | PMID 35348774 Get It

Abstract Background Pancreatic neuroendocrine tumors (pNETs) are rare cancers with outcomes determined by multiple factors including grade, stage, and clinical presentation. In this study, we aimed to determine the prognosis of patients with pNETs using a large population-based database. Materials and Methods In this population-based study, we identified patients with pNETs from the SEER 18 registry (2000-2016) using a combination of ICD-O-3 and histology codes. We calculated age-adjusted incidence rates using SEER*Stat 8.3.5. In addition, we analyzed overall survival (OS) using the Kaplan-Meier method, and investigated prognostic factors using a multivariable Cox proportional hazards model. Results A total of 8944 pNETs patients were identified. Annual incidence rates increased from 0.27 to 1.00 per 100 000. This was largely explained by an increase in number of patients diagnosed with localized disease in more recent years (2012-2016). Median OS was 68 months (95% CI [64, 73]) and 5-year OS rates in localized, regional, and metastatic disease were 83%, 67%, and 28%, respectively. There was a significant improvement in OS for patients diagnosed between 2009 and 2016 (median OS 85 months) compared with those diagnosed between 2000 and 2008 (median OS 46 months) (HR 0.66; 95% CI [0.62, 0.70]). This improvement in OS was consistent across all stages. Conclusions and Relevance This study shows a steady increase pNETs incidence with notable stage migration to earlier stages in recent years. This increase in incidence is accompanied by a significant improvement in survival across different disease stages.
Dynamic Supination in Congenital Clubfoot: A Modified Delphi Panel Approach to Standardizing Definitions and Indications for Treatment
Baskar, Danika, Hosseinzadeh, Pooya, Mosca, Vincent, Bouchard, Maryse, Aroojis, Alaric, Arkader, Alexandre, Cidambi, Emily, Denning, Jaime, Eastwood, Deborah, Gantsoudes, George, Kelly, Derek M., Kishta, Waleed, Masquijo, Javier, May, Collin, Milbrandt, Todd, Nichols, Louise R., Frick, Steven, Baskar, Danika, Hosseinzadeh, Pooya, Mosca, Vincent, Bouchard, Maryse, Aroojis, Alaric, Arkader, Alexandre, Cidambi, Emily, Denning, Jaime, Eastwood, Deborah, Gantsoudes, George, Kelly, Derek M., Kishta, Waleed E. , Masquijo, Javier, May, Collin, Milbrandt, Todd, Nichols, L. Reid , Frick, Steven

Mayo Clinic

Journal of Pediatric Orthopaedics | February 18, 2022 | Volume: 42 | Issue: 5 | Pages: e459-e465

10.1097/bpo.0000000000002119 | PMID 35180725 Get It

Background: Dynamic supination is a well-recognized cause of congenital clubfoot deformity relapse. However, there is no consensus on how to diagnose it and there are varied approaches in its management. This study aims to define dynamic supination and indications for treatment by presenting consensus from an international panel of experts using a modified Delphi panel approach. Methods: An international panel of 15 pediatric orthopaedic surgeons with clinical and research expertise in childhood foot disorders participated in a modified Delphi panel on dynamic supination in congenital clubfoot. Panelists voted on 51 statements using a 4-point Likert scale on dynamic supination, clinical indications for treatment, operative techniques, and postoperative casting and bracing. All panelists participated in 2 voting rounds with an interim meeting for discussion. Responses were classified as unanimous consensus (100%), consensus (80% or above), near-consensus (70% to 79%), and indeterminate (69% or less). Results: Consensus was achieved for 34 of 51 statements. Panelists agreed dynamic supination is present when the forefoot is supinated during swing phase of gait with initial contact on the lateral border of the foot. There was also agreement that dynamic supination results from muscle imbalance between the tibialis anterior and the peroneus longus and brevis. There was no consensus on observation of hindfoot varus in dynamic supination, operative indications for posterior release of the ankle joint, or incisional approach for tibialis anterior tendon transfer. Reference to the calcaneopedal unit concept, planes of movement, and phases of gait were deemed important factors for consideration when evaluating dynamic supination. Conclusions: Consensus statements from the Delphi panel can guide diagnosis and treatment of dynamic supination in clubfoot deformity relapse, including clinical decision making regarding preoperative casting, surgical approach, and postoperative immobilization. Near-consensus and indeterminate statements may be used to direct future areas of investigation. Level of Evidence: Level V.
MR Angiography Series: Noncardiac Chest MR Angiography
François, Christopher J. , Hecht, Elizabeth M. , Roditi, Giles , Finn, J. Paul , François, Christopher , Finn, J Paul

Mayo Clinic

RadioGraphics | February 18, 2022 | Volume: 42 | Issue: 2 | Pages: E48-E49

10.1148/rg.210212 | PMID 35179985 Get It

Association of hypothyroidism with outcomes in hospitalized adults with COVID‐19: Results from the International SCCM Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry
Bogojevic, Marija , Bansal, Vikas , Pattan, Vishwanath , Tekin, Aysun , Sharma, Mayank , Nou, Abigail T. La, Hanson, Andrew C. , Schulte, Phillip J. , Qamar, Shahraz , Morales, Diana J. Valencia , Perkins, Nicholas , Kaufman, Margit, Melamed, Roman , Christie, Amy B. , Tarabichi, Yasir , Heavner, Smith F. , Kumar, Vishakha K. , Bhagra, Sumit , Lal, Amos , Domecq, Juan Pablo , Group, Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry Investigator, Koritala, Thoyaja , Asghar, Muhammad Sohaib , Singh, Romil , La Nou, Abigail T, Zec, Simon , Valencia Morales, Diana J , Denson, Joshua L , Gajic, Ognjen , Kashyap, Rahul , Lal, Amos , Domecq, Juan Pablo , Bansal, Vikas , Asghar, Muhammad S , Tekin, Aysun , Domecq Graces, Juan Pablo , Nou, Abigail La, LeMahieu, Allison , Deo, Neha , Denson, Joshua L. , Banner‐Goodspeed, Valerie , Walkey, Allan J. , Gajic, Ognjen , Kashyap, Rahul , Group, Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID‐19 Registry Investigator

Mayo Clinic

Clinical Endocrinology | February 18, 2022 | Volume: 101 | Issue: 1 | Pages: 85-93

10.1111/cen.14699 | PMID 35180316 Get It

AbstractIntroductionCoronavirus disease 2019 (COVID‐19) is associated with high rates of morbidity and mortality. Primary hypothyroidism is a common comorbid condition, but little is known about its association with COVID‐19 severity and outcomes. This study aims to identify the frequency of hypothyroidism in hospitalized patients with COVID‐19 as well as describe the differences in outcomes between patients with and without pre‐existing hypothyroidism using an observational, multinational registry.MethodsIn an observational cohort study we enrolled patients 18 years or older, with laboratory‐confirmed severe acute respiratory syndrome coronavirus‐2 infection between March 2020 and February 2021. The primary outcomes were (1) the disease severity defined as per the World Health Organization Scale for Clinical Improvement, which is an ordinal outcome corresponding with the highest severity level recorded during a patient's index COVID‐19 hospitalization, (2) in‐hospital mortality and (3) hospital‐free days. Secondary outcomes were the rate of intensive care unit (ICU) admission and ICU mortality.ResultsAmong the 20,366 adult patients included in the study, pre‐existing hypothyroidism was identified in 1616 (7.9%). The median age for the Hypothyroidism group was 70 (interquartile range: 59–80) years, and 65% were female and 67% were White. The most common comorbidities were hypertension (68%), diabetes (42%), dyslipidemia (37%) and obesity (28%). After adjusting for age, body mass index, sex, admission date in the quarter year since March 2020, race, smoking history and other comorbid conditions (coronary artery disease, hypertension, diabetes and dyslipidemia), pre‐existing hypothyroidism was not associated with higher odds of severe disease using the World Health Organization disease severity index (odds ratio [OR]: 1.02; 95% confidence interval [CI]: 0.92, 1.13; p = .69), in‐hospital mortality (OR: 1.03; 95% CI: 0.92, 1.15; p = .58) or differences in hospital‐free days (estimated difference 0.01 days; 95% CI: −0.45, 0.47; p = .97). Pre‐existing hypothyroidism was not associated with ICU admission or ICU mortality in unadjusted as well as in adjusted analysis.ConclusionsIn an international registry, hypothyroidism was identified in around 1 of every 12 adult hospitalized patients with COVID‐19. Pre‐existing hypothyroidism in hospitalized patients with COVID‐19 was not associated with higher disease severity or increased risk of mortality or ICU admissions. However, more research on the possible effects of COVID‐19 on the thyroid gland and its function is needed in the future.
The Burden of Coronavirus Disease 2019–Related Cases, Hospitalizations, and Mortality Based on Vaccination Status and Mandated Mask Use: Statewide Data From Wisconsin and Narrative Review of the Literature
D’Souza, Ryan S. , D'Souza, Ryan S , Abd-Elsayed, Alaa A

Mayo Clinic

Anesthesia & Analgesia | February 18, 2022 | Volume: 134 | Issue: 3 | Pages: 524-531

10.1213/ane.0000000000005858 | PMID 35180169 Get It

BACKGROUND: Coronavirus disease 2019 (COVID-19) cases continue to surge in the United States with the emergence of new variants. Statewide variability and inconsistency in implementing risk mitigation strategies are widespread, particularly in regards to enforcing mask mandates and encouraging the public to become fully vaccinated. METHODS: This is a cross-sectional study conducted on July 31, 2021, utilizing publicly available data from the Wisconsin Department of Health Services. The authors abstracted data on total COVID-19–related cases, hospitalizations, and deaths in the state of Wisconsin. The primary objective was comparison of total COVID-19–related cases, hospitalizations, and deaths in vaccinated versus unvaccinated people in the state of Wisconsin over a 31-day period (July 2021). Furthermore, we also performed a narrative review of the literature on COVID-19–related outcomes based on mask use and vaccination status. RESULTS: In the state of Wisconsin during July 2021, total COVID-19 cases was 125.4 per 100,000 fully vaccinated people versus 369.2 per 100,000 not fully vaccinated people (odds ratio [OR] = 0.34, 95% confidence interval [CI], 0.33–0.35; P < .001). Total COVID-19 hospitalizations was 4.9 per 100,000 fully vaccinated people versus 18.2 per 100,000 not fully vaccinated people (OR = 0.27, 98% CI, 0.22–0.32; P < .001). Total COVID-19 deaths was 0.1 per 100,000 fully vaccinated people versus 1.1 per 100,000 not fully vaccinated people (OR = 0.09, 95% CI, 0.03–0.29; P < .001). Narrative review of the literature demonstrated high vaccine effectiveness against COVID-19 infection prevention (79%–100% among fully vaccinated people), COVID-19–related hospitalization (87%–98% among fully vaccinated people), and COVID-19–related death (96.7%–98% among fully vaccinated people). Studies have also generally reported that mask use was associated with increased effectiveness in preventing COVID-19 infection ≤70%. CONCLUSIONS: Strict adherence to public mask use and fully vaccinated status are associated with improved COVID-19–related outcomes and can mitigate the spread, morbidity, and mortality of COVID-19. Anesthesiologists and intensivists should adhere to evidence-based guidelines in their approach and management of patients to help mitigate spread.
An IL-9–pulmonary macrophage axis defines the allergic lung inflammatory environment
Fu, Yongyao , Wang, Jocelyn , Zhou, Baohua , Pajulas, Abigail , Gao, Hongyu , Ramdas, Baskar , Koh, Byunghee , Ulrich, Benjamin J. , Yang, Shuangshuang , Kapur, Reuben , Licona-Limón, Paula , Takatsuka, Shogo , Kitamura, Daisuke , Kaplan, Mark H. , Renauld, Jean-Christophe , Paczesny, Sophie , Liu, Yunlong , Tighe, Robert M , Licona-Limón, Paula , Flavell, Richard A , Takatsuka, Shogo , Tepper, Robert S , Sun, Jie , Kaplan, Mark H , Tighe, Robert M. , Flavell, Richard A. , Sun, Jie

Mayo Clinic

Science Immunology | February 18, 2022 | Volume: 7 | Issue: 68 | Pages: No page available

10.1126/sciimmunol.abi9768 | PMID 35179949 Get It

Despite IL-9 functioning as a pleiotropic cytokine in mucosal environments, the IL-9–responsive cell repertoire is still not well defined. Here, we found that IL-9 mediates proallergic activities in the lungs by targeting lung macrophages. IL-9 inhibits alveolar macrophage expansion and promotes recruitment of monocytes that develop into CD11c + and CD11c − interstitial macrophage populations. Interstitial macrophages were required for IL-9–dependent allergic responses. Mechanistically, IL-9 affected the function of lung macrophages by inducing Arg1 activity. Compared with Arg1-deficient lung macrophages, Arg1-expressing macrophages expressed greater amounts of CCL5. Adoptive transfer of Arg1 + lung macrophages but not Arg1 − lung macrophages promoted allergic inflammation that Il9r −/− mice were protected against. In parallel, the elevated expression of IL-9, IL-9R, Arg1, and CCL5 was correlated with disease in patients with asthma. Thus, our study uncovers an IL-9/macrophage/Arg1 axis as a potential therapeutic target for allergic airway inflammation.
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach
Arber, Daniel A. , Hasserjian, Robert P. , Mathews, Vikram , Roberts, Andrew W. , Schiffer, Charles A. , Roug, Anne Stidsholt , Tefferi, Ayalew , Mathews, Vikram , Tefferi, Ayalew , Roberts, Andrew W , Arber, Daniel A , Orazi, Attilio , Cazzola, Mario , Döhner, Hartmut

Mayo Clinic

American Journal of Hematology | February 18, 2022 | Volume: 97 | Issue: 5 | Pages: 514-518

10.1002/ajh.26503 | PMID 35179244 Get It

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
Lenz, Heinz‐Josef , Breakstone, Rimini, Crysler, Oxana , Bolch, Emily, Niedzwiecki, Donna , Elsing, Alicia, Hurwitz, Herbert I. , Bekaii‐Saab, Tanios , Zemla, Tyler J, Niedzwiecki, Donna , Bekaii-Saab, Tanios S , Mettu, Niharika B , Ou, Fang‐Shu , Zemla, Tyler , Hálfdánarson, Þorvarður R. , Boland, Patrick M. , Wu, Christina , Nixon, Andrew B. , Fakih, Marwan

Mayo Clinic

JAMA Network Open | February 18, 2022 | Volume: 5 | Issue: 2 | Pages: e2149040

10.1001/jamanetworkopen.2021.49040 | PMID 35179586 Get It